Mitotic vulnerability in triple-negative breast cancer associated with LIN9 is targetable with BET inhibitors

Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, making the discovery of novel therapeutic targets for this disease imperative. Our previous analysis of the molecular mechanisms of action of Bromodomain and extraterminal protein...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Sahni, Jennifer M., Gayle, Sylvia S., Webb, Bryan M., Weber-Bonk, Kristen L., Seachrist, Darcie D., Singh, Salendra, Sizemore, Steven T., Restrepo, Nicole A., Bebek, Gurkan, Scacheri, Peter C., Varadan, Vinay, Summers, Matthew K., Keri, Ruth A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5626629/
https://ncbi.nlm.nih.gov/pubmed/28807940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-1571
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados